HomeCompareOCEL vs EQR

OCEL vs EQR: Dividend Comparison 2026

OCEL yields 72.93% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEL wins by $1.16M in total portfolio value
10 years
OCEL
OCEL
● Live price
72.93%
Share price
$2.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.20M
Annual income
$325,655.22
Full OCEL calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — OCEL vs EQR

📍 OCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCELEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEL + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEL pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEL
Annual income on $10K today (after 15% tax)
$6,198.72/yr
After 10yr DRIP, annual income (after tax)
$276,806.94/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, OCEL beats the other by $272,152.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEL + EQR for your $10,000?

OCEL: 50%EQR: 50%
100% EQR50/50100% OCEL
Portfolio after 10yr
$625.9K
Annual income
$165,565.41/yr
Blended yield
26.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

OCEL
No analyst data
Altman Z
-38.0
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEL buys
0
EQR buys
0
No recent congressional trades found for OCEL or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCELEQR
Forward yield72.93%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1.20M$47.8K
Annual income after 10y$325,655.22$5,475.61
Total dividends collected$1.03M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: OCEL vs EQR ($10,000, DRIP)

YearOCEL PortfolioOCEL Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$17,993$7,292.62$11,380$679.82+$6.6KOCEL
2$31,515$12,262.92$13,014$837.25+$18.5KOCEL
3$53,795$20,073.98$14,961$1,036.20+$38.8KOCEL
4$89,585$32,023.91$17,297$1,289.22+$72.3KOCEL
5$145,696$49,840.41$20,121$1,613.15+$125.6KOCEL
6$231,650$75,755.11$23,561$2,030.84+$208.1KOCEL
7$360,433$112,567.38$27,783$2,573.54+$332.6KOCEL
8$549,352$163,689.57$33,013$3,284.39+$516.3KOCEL
9$820,973$233,165.47$39,547$4,223.51+$781.4KOCEL
10$1,204,096$325,655.22$47,791$5,475.61+$1.16MOCEL

OCEL vs EQR: Complete Analysis 2026

OCELStock

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

Full OCEL Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this OCEL vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEL vs SCHDOCEL vs JEPIOCEL vs OOCEL vs KOOCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.